Evaluating CA125 and VAS Pain Modifications following Gnrh Analog to Exclude Superficial Endometriosis as Cause of Chronic Pelvic Pain

Roberta Venturella, Angela Sacchinelli, Erika Rania, Daniela Lico, Annalisa Di Cello, M. Rocca, Rita Mocciaro, Fulvio Zullo, Michele Morelli
In: Journal of Endometriosis and Pelvic Pain Disorders · 2015 · vol. 7(1) , pp. 27–32 · doi:10.5301/je.5000205 · W2004972564
article OA: closed CC0
View on OpenAlex View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-09 ⓘ

Evaluating CA125 and VAS pain score modifications after GnRH analog administration effectively excludes superficial endometriosis in chronic pelvic pain patients, with combined marker changes showing high diagnostic accuracy.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Background The study aim was to assess the reliability in the diagnosis of superficial endometriosis of the combined evaluation of 2 parameters: modifications of serum CA125 and VAS pain score following 1 dose of GnRH analog (GnRH-a). Methods Women with chronic pelvic pain (CPP) were managed by GnRH-a administration and diagnostic laparoscopy. Serum CA125 and VAS pain score were assessed for each patient at the early follicular phase and 2 months after the administration of 11.25 mg GnRH-a. Following laparoscopy, subjects were grouped into groups A (72 women with endometriosis) and B (46 women without endometriosis). A multivariate model for CA125 and VAS reduction and for the combination of the 2 markers was calculated using logistic regression and diagnostic performance was evaluated as the AUC of ROC curve. Main outcome measure was the accuracy of the modifications of serum CA125 levels and VAS score following GnRH-a, in patients with histological diagnosis of superficial endometriosis. Results At baseline, both groups showed similar CA125 levels and VAS scores. Two months after GnRH-a, a significant reduction (delta [Δ]) in CA125 levels and VAS pain score was observed in group A only. AUCs for ΔCA125, ΔVAS score and for combination of these 2 deltas were 0.90, 0.83 and 0.97, respectively. Conclusions The assessment of serum CA125 and VAS pain score following GnRH-a demonstrates good reliability to exclude superficial endometriosis in patients with CPP. The response to GnRH-a administration in these women could therefore be employed as an ex juvantibus criterion for endometriosis diagnosis.

My notes (saved in your browser only)

Outcome instruments

VAS-pain

Condition tags

endometriosischronic_pelvic_pain

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (24)

Source provenance

openalex
last seen: 2026-06-04T00:00:01.174412+00:00
License: CC0 · commercial use OK